{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:45Z","timestamp":1790384325803,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Argenx, US"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-01000-3","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:53:27Z","timestamp":1784112807000},"page":"2643-2657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Efgartigimod (VYVGART\u2122) Social Media Posts in Generalized Myasthenia Gravis to Understand Patient, Caregiver, and Health Care Professional Sentiments"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9261-7819","authenticated-orcid":false,"given":"Tom","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Whangbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Jarmale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"26","key":"1000_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"1000_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36(2):253\u201360.","journal-title":"Neurol Clin"},{"issue":"10","key":"1000_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1000_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","volume":"26","author":"A Breiner","year":"2016","unstructured":"Breiner A, Widdifield J, Katzberg HD, et al. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disord. 2016;26(1):41\u20136.","journal-title":"Neuromuscular Disord"},{"issue":"3","key":"1000_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138.","journal-title":"Drugs"},{"issue":"1","key":"1000_CR6","volume":"15","author":"S Kanchan","year":"2023","unstructured":"Kanchan S, Gaidhane A. Social media role and its impact on public health: a narrative review. Cureus. 2023;15(1):e33737.","journal-title":"Cureus"},{"key":"1000_CR7","doi-asserted-by":"publisher","first-page":"205520762412517","DOI":"10.1177\/20552076241251715","volume":"10","author":"C Murray","year":"2024","unstructured":"Murray C, Mitchell L, Tuke J, Mackay M. Revealing patient-reported experiences in healthcare from social media using thedesign-acquire-process-model-analyse-visualise framework. Digit Health. 2024;10:20552076241251716.","journal-title":"Digit Health"},{"key":"1000_CR8","doi-asserted-by":"publisher","first-page":"1274688","DOI":"10.3389\/fmed.2024.1274688","volume":"11","author":"P Cimiano","year":"2024","unstructured":"Cimiano P, Collins B, De Vuono MC, et al. Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators. Front Med. 2024;11:1274688.","journal-title":"Front Med"},{"issue":"5","key":"1000_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40264-024-01409-5","volume":"47","author":"D Wessel","year":"2024","unstructured":"Wessel D, Pogrebnyakov N. Using social media as a source of real-world data for pharmaceutical drug development and regulatory decision making. Drug Saf. 2024;47(5):495\u2013511.","journal-title":"Drug Saf"},{"key":"1000_CR10","doi-asserted-by":"publisher","DOI":"10.52731\/liir.v006.381","author":"W-S Peng","year":"2025","unstructured":"Peng W-S, Ho C-M, Shih J-L, Huang C-D. The process of content analysis for narrative medicine: methodological exploration and AI applications. IIAI Lett Inform Interdiscipl Res. 2025. https:\/\/doi.org\/10.52731\/liir.v006.381.","journal-title":"IIAI Lett Inform Interdiscipl Res"},{"issue":"10","key":"1000_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/bmjqs-2017-006457","volume":"26","author":"R Rozenblum","year":"2017","unstructured":"Rozenblum R, Greaves F, Bates DW. The role of social media around patient experience and engagement. BMJ Qual Saf. 2017;26(10):845\u20138.","journal-title":"BMJ Qual Saf"},{"issue":"1","key":"1000_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57825-1","volume":"14","author":"A Anderson","year":"2024","unstructured":"Anderson A, Pesa J, Choudhry Z, et al. Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations. Sci Rep. 2024;14(1):7271.","journal-title":"Sci Rep"},{"key":"1000_CR13","unstructured":"Argenx US. VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use. Highlights of Prescribing Information. FDA; updated April\u00a02025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761304s010lbl.pdf. Accessed 19 Nov 2025."},{"issue":"7","key":"1000_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"1000_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard Jr.","year":"2023","unstructured":"Howard JF Jr., Bril V, Vu T, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase\u00a03 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023;14:1284444.","journal-title":"Front Neurol"},{"issue":"4","key":"1000_CR16","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","volume":"270","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Barnett C, Vu T, et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase\u00a03 study (ADAPT). J Neurol. 2023;270(4):2096\u2013105.","journal-title":"J Neurol"},{"issue":"11","key":"1000_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40265-024-02101-9","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA. Efgartigimod: a review in generalised myasthenia gravis. Drugs. 2024;84(11):1463\u201374.","journal-title":"Drugs"},{"key":"1000_CR18","doi-asserted-by":"publisher","first-page":"1147489","DOI":"10.3389\/fpubh.2023.1147489","volume":"11","author":"T Hughes","year":"2023","unstructured":"Hughes T, Anderson AE, Habib AA, et al. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. 2023;11:1147489.","journal-title":"Front Public Health"},{"issue":"5","key":"1000_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ekir.2021.02.030","volume":"6","author":"C Vasilica","year":"2021","unstructured":"Vasilica C, Oates T, Clausner C, et al. Identifying information needs of patients with IgA nephropathy using an innovative social media\u2013stepped analytical approach. Kidney Int Rep. 2021;6(5):1317\u201325.","journal-title":"Kidney Int Rep"},{"key":"1000_CR20","doi-asserted-by":"publisher","first-page":"1474347","DOI":"10.3389\/fneur.2024.1474347","volume":"15","author":"D Legg","year":"2024","unstructured":"Legg D, Meisel A, Stein M, et al. Myasthenia gravis: utilising cross-platform quantitative content analysis to uncover and validate unmet needs. Front Neurol. 2024;15:1474347.","journal-title":"Front Neurol"},{"issue":"1","key":"1000_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1057\/s41599-023-01820-w","volume":"10","author":"L Alhafez","year":"2023","unstructured":"Alhafez L, Rubio-Rico L, Diez-Bosch M. Healthcare professionals\u2019 editorial opinions on communicating with the public: shifting social media hesitancies. Humanit Soc Sci Commun. 2023;10(1):1\u201317.","journal-title":"Humanit Soc Sci Commun"},{"key":"1000_CR22","doi-asserted-by":"publisher","unstructured":"Petrovi\u0107 L, Mandi\u0107-Raj\u010devi\u0107 S. Social listening in the age of Infodemics: an AI-supported rapid risk assessment framework for public health threats. 2026. [Preprint]. Available from: https:\/\/doi.org\/10.21203\/rs.3.rs-9200680\/v1.","DOI":"10.21203\/rs.3.rs-9200680\/v1"},{"key":"1000_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2023.100079","volume":"7","author":"SB Mali","year":"2023","unstructured":"Mali SB. Social media in health care\u2014ethically challenging\u2014dangerous but attractive\u2013use with caution. Oral Oncol Rep. 2023;7:100079.","journal-title":"Oral Oncol Rep"},{"issue":"01","key":"1000_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.15265\/IY-2015-001","volume":"24","author":"K Denecke","year":"2015","unstructured":"Denecke K, Bamidis P, Bond C, et al. Ethical issues of social media usage in healthcare. Yearb Med Inform. 2015;24(01):137\u201347.","journal-title":"Yearb Med Inform"},{"issue":"3","key":"1000_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/15562646211002744","volume":"16","author":"G Samuel","year":"2021","unstructured":"Samuel G, Chubb J, Derrick G. Boundaries between research ethics and ethical research use in artificial intelligence health research. J Empir Res Hum Res Ethics. 2021;16(3):325\u201337.","journal-title":"J Empir Res Hum Res Ethics"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01000-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:14Z","timestamp":1790380994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01000-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01000-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tom Hughes is an employee of argenx. Albert Whangbo, Swati Shukla, Aditya Batra, and Shreyas Jarmale are employees and serve as paid consultants for argenx. At the time of study conduct, Kaushik Bhattacharya and Anshul Sharma were employees of ZS Associates and served as paid consultants for argenx.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this study, as it did not involve human participants or identifiable personal data. Adverse events or product complaints reported in the posts were recorded and shared with argenx.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}